Intestinal Microbiota and Thyroid Cancer

NCT03543891 | Completed

• 1 other identifier: Yunwei Wei 2018-05-20
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Thyroid cancer (TC), the most common malignancy of the endocrine system, is currently the fifth most common malignancy diagnosed in women (1). The incidence of TC in the United States has increased by an average of 3% per year over the past 4 decades. Much progress has been made in exploring the etiology and pathogenesis of thyroid cancer, while the exact etiology remains unknown, TC is thought to arise from interactions between genetic susceptibility factors, epigenetic effects, and various environmental factors. Besides the improvement of diagnosis, TC increasing incidence emphasize that other important factors such as the environment play an important role in disease pathogenesis. While microbiota as an environment factor to some cancers accept widespread attention, if microbiota also as a risk factor for TC, it is worthy to be considered.

Conditions

Microbiota

Keywords

Gut microbiota; 16S rRNA gene; Thyroid cancer; Metabonomics

Outcome Measures

Primary Outcomes (1)

• Transcriptional changes in gut microbiota

  The microbiota measured by 16S rRNA gene

  Baseline

Secondary Outcomes (1)

• Metabolic changes in gut microbiota

  Baseline

Study Arms (2)

Control group

50 healthy volunteers were included in the healthy control group

Thyroid cancer group

50 patients of thyroid cancer were included

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All patients were included according to the inclusion and exclusion criteria

You may qualify if:

• Aged 18 to 65 years
• Patients of thyroid cancer

You may not qualify if:

• Pregnancy
• Lactation
• Cigarette smoking
• Alcohol addiction
• Hypertension
• Diabetes mellitus
• Lipid dysregulation
• BMI \> 27
• Recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine
• History of disease with an autoimmune component, such as MS, rheumatoid arthritis, IBS, or IBD
• History of malignancy or any gastrointestinal tract surgery

Sponsors & Collaborators

• First Affiliated Hospital of Harbin Medical University: lead

Study Sites (1)

First affiliated hospital of Harbin medical university

Harbin, Heilongjiang, 150001, China

Location

MeSH Terms

Conditions

Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Study Officials

• Yunwei Wei

  First Affiliated Hospital of Harbin Medical University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 21, 2018
• First Posted: June 1, 2018
• Study Start: September 1, 2017
• Primary Completion: February 28, 2018
• Study Completion: April 30, 2018
• Last Updated: June 27, 2018

Record last verified: 2017-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)